Delcath Q4 revenue $15.1M, positive adjusted EBITDA; FY revenue $37.2M, no debt

DELCATH SYSTEMS, INC.

Q4 total revenue $15.1M ($13.7M HEPZATO US, $1.4M CHEMOSAT Europe); FY total $37.2M.
Q4 net loss narrowed to $3.4M from $11.1M; FY net loss $26.4M from $47.7M.
Q4 non-GAAP adjusted EBITDA positive $4.6M; FY adjusted EBITDA loss $2.5M.
Year-end cash & investments $53.2M; no debt; warrant exercises generated $41.3M in 2024.
16 active US centers; FDA clearance for Phase 2 HEPZATO trial in mCRC; NCCN update recommends HEPZATO for mUM.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.